RxDoctor Payments Data

Rajat Gulati, MD

Nephrology · Alexandria, LANPI 1992972152

Payments from drug & device makers

$5,053in general payments, 2019–2025

Across 243 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$779
  • AstraZeneca$716
  • Bayer$567
  • Vifor Pharma, Inc.$533
  • Otsuka America Pharmaceutical, Inc.$532
  • Calliditas Therapeutics US Inc.$330
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$2004%
  • Food & beverage$4,64592%
  • Education$2084%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,053 in reported general payments places this provider in the 70th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$581,753
Medicare patients
782
Services billed
5,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide61$187,705
AuryxiaFerric Citrate49$139,555
XphozahTenapanor Hcl31$127,935
FarxigaDapagliflozin Propanediol103$69,338
Tolvaptan22$29,937
Sevelamer Carbonate128$14,799
LokelmaSodium Zirconium Cyclosilicate19$14,680
JanuviaSitagliptin Phosphate12$7,046
JardianceEmpagliflozin13$6,385
Torsemide321$3,755
Calcitriol288$2,554
Dexlansoprazole DrDexlansoprazole12$1,923
Midodrine Hcl26$1,859
Losartan Potassium297$1,833
Nifedipine ErNifedipine85$1,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$779$187,70561 claims
Akebia Therapeutics IncAuryxia$253$139,55549 claims
AstraZenecaFarxiga, Lokelma$716$84,018122 claims
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$38$29,93722 claims
Boehringer IngelheimJardiance$22$6,38513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →